Cardiol Therapeutics (CRDL) Stock Price, News & Analysis

Company Overview

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Key Stats

• Today's Range: $1.42 to $1.54
• 50-Day Range: $1.06 to $1.52
• 52-Week Range: $0.77 to $2.63
• Volume: 368,415 shs
• Average Volume: 309,476 shs
• Market Capitalization: $125.30 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Buy

Cardiol Therapeutics Stock Analysis - MarketRank™

Cardiol Therapeutics scored higher than 41% of companies evaluated by MarketBeat, and ranked 645th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Cardiol Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Cardiol Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cardiol Therapeutics are expected to grow in the coming year, from ($0.33) to ($0.30) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cardiol Therapeutics is -4.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cardiol Therapeutics is -4.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cardiol Therapeutics has a P/B Ratio of 6.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.43% of the float of Cardiol Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cardiol Therapeutics has a short interest ratio ("days to cover") of 9.4.

Change versus previous month

Short interest in Cardiol Therapeutics has recently decreased by 4.02%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cardiol Therapeutics does not currently pay a dividend.

Dividend Growth

Cardiol Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.43% of the float of Cardiol Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cardiol Therapeutics has a short interest ratio ("days to cover") of 9.4.

Change versus previous month

Short interest in Cardiol Therapeutics has recently decreased by 4.02%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

7 people have searched for CRDL on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.

MarketBeat Follows

3 people have added Cardiol Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cardiol Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.25% of the stock of Cardiol Therapeutics is held by insiders.

Percentage Held by Institutions

Only 12.49% of the stock of Cardiol Therapeutics is held by institutions.

CRDL Stock Analysis - Frequently Asked Questions

How have CRDL shares performed this year?

Cardiol Therapeutics' stock was trading at $1.28 on January 1st, 2025. Since then, CRDL shares have increased by 18.4% and is now trading at $1.5160.

How were Cardiol Therapeutics' earnings last quarter?

Cardiol Therapeutics Inc. (NASDAQ:CRDL) announced its quarterly earnings data on Monday, March, 31st. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01.

How do I buy shares of Cardiol Therapeutics?

Shares of CRDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cardiol Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cardiol Therapeutics investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT ().

Company Calendar

• Last Earnings: 3/31/2025
• Today: 7/06/2025
• Next Earnings (Estimated): 7/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CRDL
• CIK: 1702123
• Web: www.cardiolrx.com
• Phone: (289) 910-0850
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.00
• High Stock Price Target: $9.00
• Low Stock Price Target: $7.00
• Potential Upside/Downside: +427.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.77 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -209.63%
• Return on Assets: -141.09%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 3.26
• Quick Ratio: 3.26

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.22 per share
• Price / Book: 6.89

Miscellaneous

• Outstanding Shares: 82,650,000
• Free Float: 78,311,000
• Market Cap: $125.30 million
• Optionable: Not Optionable
• Beta: 1.04